NCT07844213Completed
Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 30 Aug 2026
- Start date
- 25 Aug 2022
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- China National Center for Cardiovascular Diseases
- NCT number
- NCT07844213
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 25 Aug 2022 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other causes of PAH include pulmonary hypertension associated with left heart disease (valve disease)
- Other types of CHD-PAH, including Eisenmenger syndrome, PAH with small defects, etc.
- After evaluating the acute pulmonary vasodilation test by right heart catheterization, the result shows that the surgical prognosis is poor, and those who are not suitable for surgical treatment should not undergo surgical treatment.
- There are other surgical contraindications, including severe systemic diseases, severe mental disorders, severe cognitive dysfunction, and physical conditions that cannot tolerate surgery.
Other
- Cannot provide informed consent
Who the study is looking for
- Male or female aged 18 to 65
- Patients with congenital heart disease and pulmonary hypertension with clear diagnosis
- Pulmonary vascular resistance index (PVR) in hemodynamics of right heart catheterization before surgical repair: hemodynamics of right heartcatheterization before surgery conforms to "gray zone standard" (PVR: 4-8 Wood\* m2, QP/QS \> 1.5), acute vascular reaction test meets the positive standard (PVR: \< 4 Wood\* m2)
- Successfully performed surgical repair of congenital heart disease to close the defect
- Sign informed consent form
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital; National Center for Cardiovascular Diseases Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.